BioQuest, a former biotechnology and innovation company, today announced the appointment of Ed Preble as its new Chief Technology Officer (CTO). The announcement comes on the heels of BioQuest’s acquisition of BotMakers, a cutting-edge conversational AI platform-firmly establishing BioQuest as a transformative leader in the conversational AI technology sector.
This strategic expansion marks a bold evolution of BioQuest’s mission, placing the company at the powerful intersection of biotech, artificial intelligence, and intelligent automation.
“With BotMakers, we entered the conversational AI space. With Ed Preble, we’re now positioned to define it,” said Trent Daniel , CEO of BioQuest. “Ed is not just a CTO-he’s a force for transformation. He builds the systems, teams, and strategies that take companies from potential to performance, and we couldn’t be more excited to welcome him aboard.”
Ed Preble: Architect of Innovation, Execution, and Scalable AI
With over 40 years of experience driving technology innovation and business growth, Ed Preble brings an elite combination of strategic vision, deep technical expertise, and entrepreneurial execution to BioQuest. His appointment reinforces BioQuest’s commitment to dominating the conversational AI space with best-in-class platforms that combine automation, intelligence, and impact.
Ed’s experience spans:
- AI and SaaS innovation
- Telecom and omnichannel automation
- Real estate tech and enterprise infrastructure
- High-growth startup leadership and M&A strategy
He holds degrees in Business and Economics and previously served as a university professor of eCommerce at San Jose State University -where he authored one of the earliest textbooks on digital transformation. He’s a builder of platforms, a leader of agile teams, and a strategist who merges technical depth with business precision.
“Joining BioQuest is about more than technology-it’s about building a category-defining future,” said Preble. “Conversational AI isn’t just a feature. It’s the new interface for business, healthcare, biotech-everything. We’re setting the standard.”
Powering the Future of Intelligent Engagement
BioQuest’s acquisition of BotMakers was a strategic leap forward. With Preble’s leadership, the company is scaling rapidly to offer an integrated suite of AI-powered tools and platforms, including:
- Conversational AI agents for lead engagement, qualification, and scheduling
- Omnichannel social media automation
- AI-generated funnels, CRM automations, and voice interaction systems
- Biotech-specific AI solutions for clinical communication, research workflows, and patient engagement
These capabilities solidify BioQuest’s place as a transformative leader in the global conversational AI technology sector, uniquely positioned to deliver across both digital and life science domains.
A Unified Vision for Innovation and Impact
With Preble as CTO, BioQuest will:
- Expand its AI platform offerings into biotech, healthcare, and B2B sectors
- Launch rapid MVPs and product iterations aligned with evolving market needs
- Scale conversational interfaces that enhance both enterprise operations and customer experience
- Drive automation-first strategies that reduce costs, increase engagement, and generate new revenue streams
“At BioQuest, we’re combining the intelligence of biology with the intelligence of machines,” said Preble. “We’re not just automating interactions-we’re creating ecosystems that learn, evolve, and deliver value at scale.”
About BioQuest
BioQuest (OTC PINK:BQST) With the acquisition of BotMakers, BioQuest has emerged as a transformative leader in the conversational AI technology sector, building platforms that empower businesses to automate engagement, scale operations, and unlock new levels of efficiency and growth.
For more information, visit bioquestcorp.com
